An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes  by Sayyed, Sufyan G. et al.
An orally active chemokine receptor CCR2 antagonist
prevents glomerulosclerosis and renal failure in type
2 diabetes
Sufyan G. Sayyed1, Mi Ryu1, Onkar P. Kulkarni1, Holger Schmid1, Julia Lichtnekert1, Sabine Gru¨ner2,
Luke Green2, Patrizio Mattei2, Guido Hartmann2 and Hans-Joachim Anders1
1Nephrologisches Zentrum, Medizinische Poliklinik, University of Munich, Germany and 2Pharma Research and Early Development,
Hoffmann La Roche, Basel, Switzerland
The progression of diabetic nephropathy is associated with
an infiltration of macrophages expressing different
phenotypes. As classically activated chemokine receptor
CCR2þ macrophages are thought to drive tissue
inflammation and remodeling, we tested whether blocking
CCR2 could reduce intrarenal inflammation and prevent
glomerulosclerosis in type 2 diabetes. This was achieved with
RO5234444, an orally active small-molecule CCR2 antagonist
that blocks ligand binding, its internalization, and monocyte
chemotaxis. Male type 2 diabetic db/db mice were
uninephrectomized to increase glomerular hyperfiltration to
accelerate the development of glomerulosclerosis. From
16 weeks until killing at 24 weeks of age, mice were chow fed
with or without admixed antagonist to achieve a trough
plasma concentration above IC50 for binding in the mouse.
CCR2 blockade reduced circulating monocyte levels, but did
not affect total leukocyte or neutrophil numbers, and was
associated with a reduction in the number of macrophages
and apoptotic podocytes in the glomerulus. This treatment
resulted in a higher total number of podocytes, less
glomerulosclerosis, reduced albuminuria, and a significantly
improved glomerular filtration rate. This successful pre-
clinical trial suggests that this antagonist may now be ready
for testing in humans with the nephropathy of diabetes
mellitus.
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Diabetic nephropathy (DN) is a leading cause of end-stage
renal disease despite hyperglycemia control and blockade of
the angiotensin system.1,2 Hence, additional treatment strat-
egies are required to reduce the incidence of end-stage
diabetic kidney disease. Histologically, DN is characterized by
glomerulosclerosis, a result of increasing accumulation of
extracellular matrix and podocyte loss.3 The slowly progres-
sive remodeling of the glomerular architecture is triggered by
hyperglycemia during the early stage but involves additional
pathomechanisms during later stages of the disease.4,5 Activa-
tion of local inflammation has now been added onto the
list of mechanisms inducing tissue remodeling during
DN in mice and humans.6,7 For example, mycophenolate
mofetil, methotrexate, or irradiation reduce urinary albumin
excretion, and glomerulosclerosis in rats with streptozotocin-
induced diabetes.8,9 Yet, the molecular and cellular mechan-
isms of intrarenal inflammation in DN remain poorly
characterized. Human renal biopsy studies have revealed that
macrophages accumulate in the glomeruli during DN, a
finding mirrored by mouse models of DN, such as obese and
hyperinsulinemic db/db mice.10–12 Macrophages mediate
immunopathology and tissue remodeling in both non-renal
and renal diseases, and blocking macrophage recruitment can
prevent the progression of many types of kidney disease
models.13 However, reducing macrophage numbers can also
aggravate glomerular immunopathology when proinflamma-
tory (M1) cells remain the predominant macrophage
phenotype.14,15 Obviously, modulating the macrophage
phenotype is as important as reducing their overall number
to prevent glomerular damage. Classically activated chemo-
kine receptor CCR2þ macrophages represent one end of the
spectrum as they produce high amounts of proinflammatory
cytokines and reactive oxygen species upon stimulation,
which triggers tissue damage and inflammation in vivo.16
Alternatively activated (M2) macrophages represent the other
end of the spectrum as they produce anti-inflammatory
factors such as interleukin-10 and transforming growth
factor-b upon stimulation.16 It is now generally accepted that
other immunoregulatory macrophage phenotypes exist, but
efforts to define them during different stages of kidney
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diseases are still ongoing.13 The proven role of transforming
growth factor-b in the pathogenesis of DN argues for a
contribution of alternatively activated macrophages.17 How-
ever, data documenting the expression and functional role of
CC-chemokine monocyte chemoattractant protein 1 (MCP-
1/CCL2) in DN also suggest a role in recruiting activated
monocytes through the CCL2 receptor CCR2.18 Diabetic
patients excrete high levels of CCL2 in the urine.19–21 CCL2 is
expressed by human mesangial cells exposed to either high
glucose concentrations or advanced glycation end pro-
ducts.22,23 CCL2 recruits CCR2þ monocytes from the bone
marrow to the circulation and from there to extravascular
compartments such as the glomerulus.24 CCL2-deficient type
1 or type 2 diabetic mice have lower glomerular macrophage
counts and lesser glomerular injury,25,26 and late onset of
CCL2 blockade with RNA aptamers prevented glomerulo-
sclerosis and renal failure in type 2 diabetic db/db mice.27,28
Theoretically, small-molecule CCR2 antagonists may offer
two advantages over the parenteral administration of CCL2
RNA aptamers or neutralizing antibodies against the ligand.
First, targeting CCR2 would also block CCL8 and CCL16,
two additional monocyte-attracting CCR2 agonists. Second,
small-molecule CCR2 antagonists could be orally available.29
Therefore, we developed RO5234444, an orally available
small-molecule CCR2 antagonist.
We hypothesized that therapeutic CCR2 blockade with
RO5234444 would reduce glomerular macrophage numbers
in experimental DN. We expected that this effect would
prevent diffuse glomerulosclerosis, reduce proteinuria, and
improve glomerular filtration rate (GFR), a hypothesis
supported by our results.
RESULTS
Biochemistry and functional properties of RO5234444
RO5234444 is a potent small-molecule CCR2 antagonist sel-
ected from structure–activity relationship studies (Figure 1a).
We used a radiolabeled ligand-binding assay to determine the
inhibition of CCL2 binding to CCR2 by RO5234444.
Membranes were generated from CHO cells overexpressing
either human or mouse CCR2. Ligand affinity was deter-
mined with a Kd of 0.2 nmol/l for human CCR2 and
0.6 nmol/l for mouse CCR2. The addition of RO5234444
prevented binding of CCL2 to its receptor in a concentration-
dependent manner. An IC50 of 22 and 161 nmol/l was
measured using human and mouse receptors, respectively
(Figure 1b). To determine the activity of the inhibitor in a
more physiologically relevant assay system, we used two
different read outs: chemotaxis and receptor internalization.
For chemotaxis, we used human peripheral blood mono-
nuclear cells and determined the number of monocytes that
migrated across the filter into the lower well. CCL2 induced a
robust migration of monocytes with an EC50 of 2.2±
1.4 nmol/l (n¼ 4, Figure 2a). The presence of RO5234444
inhibited the migration of monocytes in a dose-dependent
manner (IC50¼ 50.2 nmol/l). A part of G protein-coupled
receptor signaling is receptor internalization and recycling;
this mechanism is also used by CCR2. CCL2-induced
receptor internalization of CCR2 in monocytes was measured
in heparinized human blood. Increasing concentrations of
CCR2 were incubated for 30min at 37 1C before cells were
transferred to 4 1C to stop internalization. Monocytes were
identified by anti-CD14 and anti-CCR2 staining (Figure 2a).
CCL2 potently induced receptor internalization with an EC50
of 3.5±2.9 nmol/l (n¼ 18, Figure 2b), whereas the presence
of RO5234444 prevented receptor internalization. We used
the Cheng–Prussov correction and determined a Ki of
11.9±5.8 nmol/l (n¼ 5) for inhibition of CCR2 internaliza-
tion by RO5234444 (Figure 2c). The potency of a competitive
antagonist may also be described by the pA2 value, which is
generated by agonist dose-response curves in the presence of
antagonists. The parallel shift of agonist response through the
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Figure 1 | Structure of RO5234444 and binding assays.
(a) Chemical structure of RO5234444. (b) Dose-dependent
inhibition of 125J-CCL2 binding to human and mouse CCR2 were
studied by increasing concentrations of RO5234444-inhibited
binding of 125J-CCL2 (100 pmol/l) to membranes of stably
transfected CHO cells expressing human or mouse CCR2 as
described in the ‘Materials and Methods’ section. Calculation of
IC50s resulted in values of 22 nmol/l for human CCR2 and
161 nmol/l for mouse CCR2. (c) The dose response of
CCL2-induced chemotaxis of CD14þ monocytes was studied
in chemotaxis assays and revealed an EC50 of 2.2 nmol/l.
(d) Inhibition of monocyte chemotaxis using RO5234444 resulted
in an IC50 of 50.2 nmol/l.
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presence of antagonists supports that RO5234444 is a
competitive inhibitor of CCR2 (not shown). Therefore, pA2
will equal the Kd as antagonist as if antagonists and agonists
compete for binding to a single class of receptor sites. The
pA2 determined for RO5234444 was 14.8 nmol/l. To further
characterize the compound, we tested it in a mouse model
of acute monocyte infiltration. Thioglycolate was injected
intraperitoneally to induce monocyte migration into the
peritoneal cavity. The monocyte response was maximal at 6 h
(not shown). Oral gavage of RO5234444 just before
thioglycolate challenge strongly reduced this monocyte
influx, as measured by the intermediate expression of F4/80,
a monocyte/macrophage marker by flow cytometry (Figure 2d).
Uninephrectomy increases renal CCR2 mRNA levels in
db/db mice
As previously shown, early uninephrectomy accelerates
glomerulosclerosis in type 2 diabetic db/db mice.30 We
questioned whether this uninephrectomy-related acceleration
of glomerulosclerosis is associated with an increase in renal
CCR2 expression. Hence, we examined the renal expression
of CCR2 mRNA in 1 kidney (1K) or 2K db/db mice by real-
time reverse transcriptase-PCR. Kidneys of 6-week- and
6-month-old 2K db/db mice showed low CCR2 mRNA
expression (Figure 3). By contrast, early uninephrectomy was
associated with a significant increase in renal CCR2 mRNA
expression in db/db mice at 6 months of age.
CCR2 blockade reduces macrophage counts and
glomerulosclerosis in 1K db/db mice
To test whether pharmacological blockade of CCR2 with
RO5234444 affects the progression to advanced nephropathy
in db/db mice, we initiated oral RO5234444 treatment at an
age of 4 months in 1K db/db mice. A dose of 100mg/kg was
used because in pilot experiments, 100mg/kg of RO5234444,
prepared as a food admix, displayed a trough plasma con-
centration of 1.23±0.42 mg/ml, which is well above the IC50
of the mouse-binding assay. Treatment was continued for 8
weeks when urine samples and tissues were collected for
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Figure 2 | Functional assays of CCR2 blockade with
RO5234444. A whole-blood receptor internalization assay was
used to show that RO5234444 prevents CCL2-induced
internalization of CCR2 in a dose-dependent manner. Human
monocytes were detected by a size/granularity plot and
CD14-positive staining. (a) Staining of CCR2 in the presence and
absence of CCL2 is shown in a linear plot. (b) A dose response of
CCR2 internalization induced by CCL2 results in an EC50 of
3.5 nmol/l. (c) RO5234444 inhibits CCL2 (30 nmol/l)-induced
receptor internalization resulting in an IC50 of 89 nmol/l.
Dose-response curves of monocyte infiltration after
intraperitoneal thioglycolate challenge. Peritoneal monocyte
numbers were assessed 6 h after thioglycolate challenge.
RO5234444 reduced monocyte numbers in a dose-dependent
manner. (d) The graphs illustrate the mean of each score±s.d.
from all mice in each group (n¼ 8).
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Figure 3 | Effect of uninephrectomy on renal CCR2 expression
of db/db mice. Quantitative real-time RT-PCR analysis was
performed on total cDNA derived from kidneys of 6-week- or
6-month-old 2K db/db mice or 6-month-old 1K db/db mice. The
cDNA was amplified using primers specific for mCCR2 for 40 PCR
cycles. The data shown are derived from cDNA samples obtained
from 4–8 mice of each group and are expressed as ratio to
the respective 18 s rRNA expression. RT-PCR, reverse
transcriptase-PCR.
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assessment of kidney disease. Consistent with its role for
monocyte evasion from the bone marrow, RO5234444
significantly reduced the numbers of circulating monocytes
in treated 1K db/db mice, but total white blood cell and
neutrophil counts remained unaffected (Figure 4a). Blood
glucose levels or body weights were markedly elevated in all
groups of db/db mice as compared with non-diabetic mice,
but both parameters remained unaffected by RO5234444
treatment (Figure 4b and c). Consistent with our hypothesis,
CCR2 blockade significantly reduced the number of glomer-
ular macrophages by 65% and interstitial macrophages by
50% as compared with vehicle-treated db/db mice (Figure 5a
and b). This finding was associated with a significant
improvement in global glomerulosclerosis in 1K db/db mice
(Figure 5c). In fact, CCR2 blockade reduced glomerulo-
sclerosis in 1K db/db mice to the extent of glomerulosclerosis
present in age-matched 2K db/db mice (Figure 5d).
Glomerular mRNA expressions of CCL2 and CCL8 were
significantly reduced by CCR2 blockade, whereas a non-
significant trend toward lower mRNA levels was detected for
CCL7 and CCR2 (Figure 6a). This finding correlated with a
reduction in CCL2 staining positivity in cells of the
glomerular tuft, parietal epithelial cells, and proximal tubular
cells at the same time point (Figure 6b). Murine mesangial
cells cultured under high glucose conditions did not express
CCR2 mRNA, and RO5234444 did not alter the expression
level of fibronectin, laminin, collagen IVa1, and transforming
growth factor-b mRNA excluding a direct effect of
RO5234444 on mesangial cells (data not shown). These
findings show that delayed blockade of CCR2 reduces
glomerular macrophages and prevents global glomerulo-
sclerosis in uninephrectomized type 2 diabetic db/db mice.
CCR2 blockade prevents loss of glomerular podocytes in
1K db/db mice
The loss of podocytes is an important element of glomerulo-
sclerosis and glomerular function in diabetic kidney
disease.31,32 In fact, glomerulosclerosis in 1K db/db mice
was associated with a 30% reduction of glomerular Wilms’
tumor protein (WT)-1-positive podocytes (Figure 7).
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Figure 4 |CCR2 blockade and white blood counts, body weight, and blood glucose levels in 6-month-old db/db mice. (a) White blood
counts were determined by flow cytometry at 2-week intervals throughout the 8-week treatment period (4–6 months of age) as described in
the ‘Materials and Methods’ section. It is noteworthy that CCR2 blockade did not affect total leukocyte and neutrophil numbers but
reduced monocyte counts from 4 weeks of treatment as compared with untreated 1K db/db mice. **Po0.01, ***Po0.001. (b, c) Body
weight (panel b) and blood glucose levels (panel c) were also determined at 2-week intervals throughout the treatment period in 1K db/db
mice, as well as in sham-operated 2K db/db mice and in wild-type non-diabetic mice. CCR2 blockade did not affect these parameters.
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RO5234444 treatment prevented this loss of podocytes
because RO5234444-treated 1K db/db mice had significantly
higher numbers of glomerular WT-1-positive cells (Figure 7).
A quantitative assessment of TUNEL (terminal deoxynucleo-
tidyl transferase dUTP nick-end labeling)-positive ‘apoptotic’
WT-1þ podocytes revealed that CCR2 blockade significantly
reduced podocyte apoptosis in 1K db/db mice (vehicle:
1.1±0.1 versus CCR2 blockade 0.2±0.1 double-positive cells
per glomerulus, P¼ 1.3 107, Figure 8). Murine podocytes
cultured under high glucose conditions did not express CCR2
mRNA, and RO5234444 did not alter the expression level of
WT-1 mRNA excluding a direct effect of RO5234444 on
podocytes (data not shown). Thus, CCR2 blockade reduces
glomerular macrophage numbers and prevents the loss of
podocytes and glomerulosclerosis in uninephrectomized type
2 diabetic mice.
CCR2 blockade improves albuminuria and GFR in 1K
db/db mice
The beneficial effects of CCR2 blockade on glomerulosclero-
sis in 1K db/db mice should be associated with an
improvement in albuminuria and GFR. We determined
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Figure 5 |Histopathology in 6-month-old db/db mice. (a) Mac2þ cells were counted in 15 glomeruli and (b) the interstitial compartment
of 15 high power fields (HPF) per section. It is noteworthy that CCR2 blockade significantly reduced glomerular Mac2þ cells
as compared with untreated 1K db/db mice. **Po0.01 CCR2 vehicle diabetic versus non-diabetic mice, $$Po0.01 CCR2 blockade versus
untreated 1K db/db mice. (c) Renal sections from mice of all groups were stained with periodic acid Schiff and scored for the extent of
glomerulosclerosis as described in the ‘Materials and Methods’ section. Mac2 immunostaining was performed to assess glomerular
macrophage counts. Images show representative glomeruli as indicated. (d) From each mouse, 15 glomeruli from one renal section
were graded by that score. The graph illustrates the mean percentage of each score±s.e.m. from all mice in each group (n¼ 7–10).
Uninephrectomy was associated with a shift toward higher scores of sclerosis, which was reverted by CCR2 blockade. #Po0.05 1K versus
2K mice, ***Po0.001 CCR2 blockade versus untreated 1K db/db mice. PAS, periodic acid Schiff.
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albumin/creatinine ratios as a marker of proteinuria every 2
weeks during the treatment interval. RO5234444 treatment
prevented the increase in albuminuria that was observed in
vehicle-treated 1K db/db mice over time (Figure 9a).
Furthermore, fluorescein isothiocyanate-inulin clearance
kinetics were studied as a marker of GFR in db/db mice at
the end of the study. In 6-month-old db/db mice with DN,
the GFR of B300ml/min was somewhat decreased as
compared with a normal GFR of B400 ml/min in age-
matched non-diabetic control mice (Figure 9b). The sudden
GFR decline by uninephrectomy at the age of 6 weeks in
healthy mice is largely compensated throughout the sub-
sequent 4.5 months (not shown); but in combination with
type 2 diabetes, 6-month-old vehicle-treated 1K db/db mice
displayed a markedly reduced GFR of 145±47 ml/min.
CCR2 blockade significantly improved the GFR in these
mice (Figure 9b). Thus, blocking CCR2-dependent
glomerulosclerosis reduces albuminuria and improves GFR
in uninephrectomized type 2 diabetic mice.
DISCUSSION
The results of this study provide experimental evidence for
our hypothesis that therapeutic CCR2 blockade with an
orally available small-molecule antagonist can prevent diffuse
glomerulosclerosis and maintain renal function in unine-
phrectomized mice with type 2 diabetes. These data
document the functional contribution of CCR2-dependent
immunopathology to the progression of kidney disease in
uninephrectomized type 2 diabetic mice.
CCR2 is a G protein-coupled, seven-transmembrane-
spanning chemokine receptor which specifically mediates
monocyte evasion from the bone marrow and their
transmigration from the vascular to the extravascular
compartments.33 The first mechanism explains lower levels
of circulating monocytes in CCR2 antagonist-treated mice.
The latter mechanism also applies to DN because blockade of
the major CCR2 ligand, CCL2, impairs the recruitment of
intravenously injected monocytes into the glomerular and
interstitial renal compartments of uninephrectomized db/db
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Figure 6 | Effect of CCR2 blockade on glomerular chemokine expression of db/db mice. (a) Quantitative real-time RT-PCR analysis
was performed on cDNA derived from glomeruli that were harvested by laser capture microdissection from kidneys of 6-month-old vehicle-
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mice.27,28 It is noteworthy that in mice, intrinsic renal cells
such as mesangial cells and podocytes lack CCR2 expression;
therefore, we refer all intrarenal effects of CCR2 blockade
to CCR2 expression on infiltrating immune cells. CCR2 is
differentially expressed among monocyte/macrophage pheno-
types.16 CCR2 identifies a specific subset of classically activated
(M1) macrophages with proinflammatory effector functions
that contribute to tissue inflammation and damage.16 Obesity
has recently been shown to trigger the recruitment of CCR2þ
M1 macrophages into the adipose tissue,34,35 a phenomenon
inducing insulin resistance and diabetes.36,37 Vice versa, CCR2
blockade suppressed M1 macrophage accumulation, inflam-
mation, and insulin resistance in the adipose tissue of obese
db/db mice.38 Our data now propose a similar proinflamma-
tory and pathogenic role for CCR2þ macrophages in kidney
disease of uninephrectomized db/db mice. CCR2 blockade
with RO5234444 reduced the numbers of glomerular macro-
phages. This effect was associated with a better renal outcome
as documented by a reduction of extracellular glomerular
matrix, higher podocyte numbers, less albuminuria, and
higher GFR as compared with untreated db/db mice. Our
experimental approach of aggravating glomerulosclerosis in
db/db mice by early uninephrectomy may limit the inter-
pretation as some of the treatment effects could be rather
related to the consequences of uninephrectomy than to the
metabolic triggers of DN. However, glomerular hyperfiltration
is another essential pathogenic factor in DN. These data are
also consistent with previous studies that targeted the CCR2
ligand in db/db mice.26–28 It is noteworthy that 8 weeks of
CCR2 blockade with RO5234444 protected kidney disease in
uninephrectomized db/db mice to the same extent as 8 weeks
of CCL2 blockade with an RNA aptamer.27 This finding argues
against a functional importance of the additional CCR2-
activating chemokines CCL8 and CCL16 in DN beyond the
biological effects of CCR2 alone. Hence, both CCR2 and CCL2
represent valuable therapeutic targets to prevent renal failure
in type 2 diabetes. From a pharmacological point of view,
targeting the receptor favors small molecule-based drugs,
which are suitable for the preferred oral route of administra-
tion. Our study documents the feasibility of this approach in
type 2 diabetic db/db mice, which may render oral CCR2
blockade as a potential therapeutic strategy for the prevention
or treatment of DN in humans.
In summary, late onset of CCR2 blockade with
RO5234444, an orally available small-molecule antagonist,
can prevent proteinuria, glomerulosclerosis, and renal failure
in type 2 diabetic db/db mice. In view of the known beneficial
effects of CCR2 blockade on insulin resistance38 and
atherogenesis,39 therapeutic CCR2 blockade may also prevent
renal failure, as another major course for morbidity and
mortality in type 2 diabetes.
MATERIALS AND METHODS
Test compound
The CCR2 antagonist RO5234444 ((S)-4-[(E)-3-(3-Chloro-4-
fluoro-phenyl)-acryloyl]-1-[3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-
propyl]-3-methyl-piperazin-2-one) was synthesized as described
previously (PCT Int. Appl. WO2009/010429).
CCR2 antagonist-binding studies
Recombinant CHO-K1 cells stably expressing human or mouse
CCR2 (Euroscreen, Brussels, Belgium) were pelleted in 10mmol/l
ice-cold Tris-HCl, pH 7.4, 1mmol/l EDTA, and homogenized three
times using a medium Turrax Homogeniser (Sigma-Aldrich,
Munich, Germany) for 40 s at 13 500 r.p.m. at 4 1C. The homo-
genates were centrifuged for 15min at 1300 g at 4 1C. The
supernatant was centrifuged at 100 000 g for 60min at 4 1C, and
the resulting pellet was re-suspended in Tris buffer (Tris-HCl, pH
7.4, 1mmol/l EDTA, 10mmol/l MgCl2, and 10% glycerol). Aliquots
of membrane preparations were stored at 80 1C. Radioligand-
binding assays were conducted using GF/C-96-well filtration plates
(Packard Bioscience, Waltham, MA), 125J-MCP1 (Perkin-Elmer,
Waltham, MA), Filtermate 196 harvester, and a liquid scintillation
counter (TopCount, Packard Bioscience). In all, 100 pmol/l of
125J-CCR2 was incubated with 0.5 mg per well of membranes in a
binding buffer (50mmol/l HEPES, 1mmol/l CaCl2, 5mmol/l MgCl2,
0.5% bovine serum albumin 2.5, and 0.01% NaN3 adjusted to pH
7.2) for 60min at room temperature. Nonspecific binding was
determined by the addition of 50 nmol/l of unlabeled CCR2.
For IC50 determinations, RO5234444 was incubated for 60min
with membranes before the addition of radioactivity.
Monocyte chemotaxis assay in peripheral blood mononuclear
cells and whole-blood receptor internalization assay
Heparinized blood was used to prepare peripheral blood mono-
nuclear cells using Ficoll gradient centrifugation. Cells were adjusted
to 1.8 106 cells per ml in phosphate-buffered saline (PBS)/1%
bovine serum albumin. A volume of 30 ml of medium w/o CCL2 and
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Figure 7 |Glomerular podocyte counts in 6-month-old 1K
db/db mice. Renal sections were stained for the nuclear podocyte
marker WT-1 as described in the ‘Materials and Methods’ section.
Images show representative glomeruli (magnification  400).
WT-1þ cells were counted in 15 glomeruli per section. It is
noteworthy that CCR2 blockade significantly increased glomerular
WT-1þ cells as compared with untreated 1K db/db mice.
glom, glomerular; WT-1, Wilms’ tumor protein-1.
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Figure 8 |Double immunostaining for the detection of apoptotic podocytes. Renal sections from uninephrectomized db/db mice were
stained for the nuclear podocyte marker WT-1 (red color) and TUNEL (green color) to detect podocytes that are undergoing apoptosis.
DAPI (blue color) indicates all nuclei. The upper set of images displays intra-tubular casts of apoptotic podocytes (arrows) in vehicle-treated
1K db/db mice. Note also the WT-1þ podocytes in the encircled glomerular pole cut. The second set of images shows representative
glomeruli of the same group at a magnification of  400. The third set shows the same glomerulus at a higher magnification ( 1000). The
set of images at the bottom shows representative glomeruli from 1K db/db mice treated with the CCR2 antagonist at a magnification of
 400. It is noteworthy that TUNEL-positive podocytes (white arrows) were mainly observed in vehicle-treated 1K db/db mice. TUNEL,
terminal deoxynucleotidyl transferase dUTP nick-end labeling; WT-1, Wilms’ tumor protein-1.
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test compound was added into the low well of a 5 mmol/l diameter
chemotaxis plate (ChemoTX, Neuro Probe, Gaithersburg, MD).
Cells plus/minus compound were placed on top of the plate and
incubated for 90min at 37 1C in the incubator. The plate was rinsed
three times with PBS. Cells in the bottom were transferred to a 96-
well plate. A volume of 1 ml of anti-CD14 (BD Pharmingen 555397,
Mannheim, Germany) was added to each well and cell counts
determined using flow cytometry. Overall, 20ml of heparinized blood
per well was pipetted to each well of a 96-well plate. RO5234444 was
added to the blood in a final concentration starting at 10mmol/l for
15min at 37 1C. Recombinant CCR2 was added either in a dose
response starting at 100 nmol/l or at an agonist dose of 30 nmol/l to
wells containing the CCR2 antagonist. After 1 h of incubation at
37 1C, cells were washed with ice-cold PBS/1% bovine serum
albumin and 1 ml anti-CCR2 (R&D Systems, FAB151P, Wiesbaden,
Germany) and anti-CD14 (BD Pharmingen 555397) antibodies were
added. Cells were incubated for 1 h at 4 1C. Erythrocytes were then
lysed and leukocyte fixed by addition of 20 ml of FIX/lyse buffer (BD
Pharmingen 558049) and analyzed by flow cytometry.
In vivo macrophage recruitment assay
C57BL/6 mice in groups of eight were treated orally with RO5234444
with 100, 30, 10, 3, 1, 0.3, and 0.1mg/kg. Thioglycolate (4%) was
injected 30min later intraperitoneally. Six hours after the thioglycolate
challenge, mice were killed and the peritoneal cavity was washed with
7ml PBS. After centrifugation, lavage fluid was analyzed using F4/80
(anti-mouse F4/80; Acris, Heidelberg, Germany) as a monocyte/
macrophage marker in an automated cell counting system (Millipore,
Guava EasyCyte, Billerica, MA).
DN model
Male 5-week-old C57BLKS db/db were obtained from Taconic (Ry,
Denmark) and housed in filter top cages with a 12 h dark/light cycle
and unlimited access to food and water for the duration of the study.
At the age of 6 weeks, uninephrectomy (1K mice) or sham surgery
(2K mice) was performed through a 1-cm flank incision in db/db
mice.30 In mice of the sham surgery groups, the kidney was left
in situ. At the age of 4 months, 1K db/db mice were divided into
groups that received standard diet or food admix that contained
RO5234444 to deliver a dose of 100mg/kg based on an daily intake
of 4 g of food a day. Treatment was continued for 8 weeks until the
age of 24 weeks when tissues were obtained for histopathological
evaluation. Blood and urine samples were obtained at monthly
intervals for analysis of blood glucose levels (Accu-Chek sensor,
Roche, Mannheim, Germany), urinary albumin (ELISA (enzyme-
linked immunosorbent assay): Bethyl Labs, Montgomery, TX), and
urinary creatinine (Jaffe´ reaction: DiaSys Diagnostic Systems,
Holzheim, Germany). All experimental procedures were approved
by the local government authorities.
Histopathological evaluation
From each mouse, parts of the kidneys were fixed in 10% formalin
in PBS and embedded in paraffin. Sections of 2-mm thickness were
stained with periodic acid-Schiff reagent.40 Glomerular sclerotic
lesions were assessed using a semi-quantitative score by a blinded
observer as follows: 0¼ no lesion, 1¼o25% sclerotic, 2¼ 25–49%
sclerotic, 3¼ 50–74% sclerotic, and 4¼ 75–100% sclerotic. Macro-
phage numbers were assessed on paraffin-embedded sections by
immunohistochemistry using anti-Mac2 (Cederlane, Burlington,
Ontario, Canada, 1:5000) as a primary antibody. Podocytes
were quantified by staining paraffin-embedded sections for WT-1
(Santa Cruz Biotechnology, Santa Cruz, CA, 1:200) for 2 h at room
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Figure 9 |Albuminuria and GFR in 6-month-old db/db mice.
(a) Urinary albumin/creatinine ratios were determined as a
functional marker of the glomerular filtration barrier at 2-week
intervals throughout the 8-week treatment period (months 4–6 of
age) as described in the ‘Materials and Methods’ section. It is
noteworthy that CCR2 blockade prevented the progressive
increase of albuminuria observed in untreated 1K db/db mice.
(b) GFR was determined by FITC-inulin clearance kinetics in all
groups at the end of the study as described in the ‘Materials and
Methods’ section. It is noteworthy that CCR2 blockade
significantly improved the GFR compared with untreated 1K
db/db mice. *Po0.05, **Po0.01 versus untreated 1K db/db mice.
Table 1 | Primers used for RT-PCR
Gene Sequence
18s Forward: GCAATTATTCCCCATGAACG
Reverse: AGGGCCTCACTAAACCATCC
Ccl2 Forward: CCTGCTGTTCACAGTTGCC
Reverse: ATTGGGATCATCTTGCTGGT
Ccl7 Forward: CTGCTTTCAGCATCCAAGTG
Reverse: TTCCTCTTGGGGATCTTTTG
Ccl8 Forward: TCTTTGCCTGCTGCTCATAG
Reverse: GAAGGGGGATCTTCAGCTTT
Tgf-b1 Forward: GGAGAGCCCTGGATACCAAC
Reverse: CAACCCAGGTCCTTCCTAAA
Fibronectin 1 Forward: GGAGTGGCACTGTCAACCTC
Reverse: ACTGGATGGGGTGGGAAT
Laminin 2 Forward: CATGTGCTGCCTAAGGATGA
Reverse: TCAGCTTGTAGGAGATGCCA
Col4a1 Forward: GTCTGGCTTCTGCTGCTCTT
Reverse: CACATTTTCCACAGCCAGAG
Nphs2 (podocin) Forward: TGACGTTCCCTTTTTCCATC
Reverse: CAGGAAGCAGATGTCCCAGT
Nphs1 (nephrin) Forward: TTAGCAGACACGGACACAGG
Reverse: CTCTTTCTACCGCCTCAACG
Abbreviation: RT-PCR, reverse transcriptase-PCR.
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temperature and subsequent incubation with a suitable secondary
antibody as described previously.41 For WT-1/TUNEL costaining, a
TUNEL staining kit was used (Roche). A total of 50 glomeruli and
15 high power fields (for interstitial cells) were analyzed per section
by a blinded observer.
Laser capture microdissection of paraffin-embedded renal
tissue
A Robot MicroBeam system (P.A.L.M., Wolfratshausen, Germany)
was used to isolate the glomeruli from formaldehyde-fixed and
paraffin-embedded renal sections. After deparaffination with 100%
xylene and rehydration in 100, 90, and 70% ethanol, B100
glomeruli per animal were isolated under direct visual control by
the focused nitrogen laser beam from the surrounding tissue, as
described recently.41 For harvesting of the samples, the energy of
the laser was increased and the microdissected glomerulus was
catapulted with a single laser shot. The detached glomeruli were
collected in a microfuge cap coated with mineral oil (Fluka Sigma-
Aldrich, Deisenhofen, Germany). Samples were stored in liquid
nitrogen until being processed further.
RNA preparation and real-time quantitative (TaqMan)
reverse transcriptase-PCR
Total RNAwas isolated from the kidneys using Qiagen RNA extraction
kit (Qiagen, Hilden, Germany) following the manufacturer’s instruc-
tions as described previously.42 After quantification, RNA quality was
assessed using agarose gels. From isolated RNA, cDNA was prepared
using reverse transcriptase (Superscript II, Invitrogen, Carlsbad, CA).
Real time-PCR was performed using SYBRGreen PCR master mix and
analyzed using a Light Cycler 480 (Roche). Gene expression values were
normalized using 18s RNA as a house keeping gene. Primers used for
amplification were obtained from Metabion (Martinsried, Germany)
and are listed in Table 1.
Glomerular filtration rate
GFR was determined by clearance kinetics of plasma fluorescein
isothiocyanate-inulin (Sigma-Aldrich, Steinheim, Germany) 5, 10, 15,
20, 35, 60, and 90min after a single bolus injection as described
previously.30 Fluorescence was determined with 485nm excitation and
read at 535nm emission. GFR was calculated based on a two-
compartment model using non-linear regression curve-fitting software
(GraphPad Prism, GraphPad Software, San Diego, CA).
Flow cytometry
Flow cytometric analyses of collected blood samples were performed
using a FACScalibur machine (BD Pharmingen) using the follow-
ing primary antibodies: anti-mouse CD45R-APC, 7/4-PE, and Ly6G-
fluorescein isothiocyanate (BD Pharmingen) as described previously.43
Cell culture experiments
Primary mesangial cells were prepared from C57BL/6 mice as des-
cribed previously44,45 and cultured in 6-well plates with Dulbecco’s
modified Eagle’s medium (Gibco/Invitrogen, Paisley, Scotland, UK)
containing 20% fetal calf serum, 1% ITS (insulin, transferrine,
selenium; Roche), 100Units/ml penicillin, and 100 mg/ml strepto-
mycin (PAA Laboratories, Pasching, Austria) at 37 1C, 5% CO2.
Murine podocytes were allowed to proliferate in the Dulbecco’s
modified Eagle’s medium containing 10% fetal calf serum,
100Units/ml penicillin, 100mg/ml streptomycin, and 10Units/ml
mouse interferon-g (ImmunoTools, Friesoythe, Germany) at
permissive temperature (33 1C), 5% CO2, as described previously.
46
Cells were differentiated under non-permissive conditions (37 1C),
5% CO2, without interferon-g supplement for 10–14 days. For in
vitro stimulation, cells were serum starved for 24 h before the
medium was changed to serum-free Dulbecco’s modified Eagle’s
medium containing low glucose (medium only, 5.6mmol/l) or high
glucose (mediumþ 24.4mmol/l glucose, Sigma-Aldrich) with or
without the 1 mmol/l CCR2 antagonist RO5234444. Supernatants
were harvested after 24 h of incubation, and cell mRNA was
harvested after 6 h of incubation.
Statistical analysis
Data are presented as mean±s.e.m. Comparison of groups was
performed using ANOVA (analysis of variance) and post hoc
Bonferroni’s correction was used for multiple comparisons. A value
of Po0.05 was considered to indicate statistical significance.
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